Edward Chu

Summary

Publications

  1. doi request reprint An update on the current and emerging targeted agents in metastatic colorectal cancer
    Edward Chu
    Division of Hematology Oncology, Department of Medicine and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA, USA
    Clin Colorectal Cancer 11:1-13. 2012
  2. pmc Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer
    Yaguang Xi
    Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36688, USA
    BMC Genomics 7:68. 2006
  3. doi request reprint Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Oncology 77:244-53. 2009
  4. doi request reprint Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 9:229-37. 2010
  5. ncbi request reprint Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy
    Edward Chu
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Support Oncol 4:243-50. 2006
  6. doi request reprint Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer
    Edward Chu
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer 115:1412-23. 2009
  7. ncbi request reprint Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
    Edward Chu
    Cancer Center 111D, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 52:S80-9. 2003
  8. ncbi request reprint Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer
    James J Lee
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 7:S16-20. 2007
  9. ncbi request reprint Translational autoregulation of thymidylate synthase and dihydrofolate reductase
    Ningwen Tai
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VACT Healthcare System, New Haven, CT 06516, USA
    Front Biosci 9:2521-6. 2004
  10. pmc Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA
    Ningwen Tai
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Biochem J 378:999-1006. 2004

Research Grants

Collaborators

Detail Information

Publications69

  1. doi request reprint An update on the current and emerging targeted agents in metastatic colorectal cancer
    Edward Chu
    Division of Hematology Oncology, Department of Medicine and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA, USA
    Clin Colorectal Cancer 11:1-13. 2012
    ....
  2. pmc Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer
    Yaguang Xi
    Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36688, USA
    BMC Genomics 7:68. 2006
    ....
  3. doi request reprint Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Oncology 77:244-53. 2009
    ..To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection...
  4. doi request reprint Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 9:229-37. 2010
    ..This study quantified the costs associated with the acquisition of chemotherapy, its administration, and the management of chemotherapy-related complications, and their effect on total patient expenditures...
  5. ncbi request reprint Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy
    Edward Chu
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Support Oncol 4:243-50. 2006
    ..Except for significantly higher QOL scores at baseline, results for the cohort of colorectal cancer patients were similar to those for patients with other cancer types in the main study population...
  6. doi request reprint Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer
    Edward Chu
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer 115:1412-23. 2009
    ..In this study, the authors measured the cost of chemotherapy-related complications during treatment with capecitabine- and 5-FU-based regimens...
  7. ncbi request reprint Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
    Edward Chu
    Cancer Center 111D, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 52:S80-9. 2003
    ..The future success of TS inhibitor compounds in the clinic may depend on novel strategies to selectively inhibit TS and on novel combination therapies to overcome cellular drug resistance...
  8. ncbi request reprint Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer
    James J Lee
    Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 7:S16-20. 2007
    ..This review will update the current status of these capecitabine-based combination regimens...
  9. ncbi request reprint Translational autoregulation of thymidylate synthase and dihydrofolate reductase
    Ningwen Tai
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VACT Healthcare System, New Haven, CT 06516, USA
    Front Biosci 9:2521-6. 2004
    ..Moreover, we present evidence showing that abrogation of these normal translational autoregulatory feedback mechanisms provides the molecular basis for the rapid development of cellular drug resistance...
  10. pmc Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA
    Ningwen Tai
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Biochem J 378:999-1006. 2004
    ..In vitro and in vivo studies further localized this cis-element to an 82 nt sequence corresponding to nt 401-482. This work provides new insights into critical elements that mediate RNA-protein interactions...
  11. ncbi request reprint Identification of a cis-acting element of human dihydrofolate reductase mRNA
    Ningwen Tai
    Department of Medicine and Pharmacology, Developmental Therapeutic Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Biochem Biophys Res Commun 369:795-800. 2008
    ..This work provides new insights into the essential molecular elements that mediate RNA-protein interactions...
  12. ncbi request reprint Current therapies for advanced colorectal cancer
    Sandhya Aggarwal
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
    Oncology (Williston Park) 19:589-95. 2005
    ..The goal of such studies is to facilitate the evolution of empiric chemotherapy to individually tailored treatments for patients with colorectal cancer...
  13. ncbi request reprint First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer
    James J Lee
    Section of Medical Oncology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Colorectal Cancer 6:S42-6. 2007
    ....
  14. doi request reprint A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer
    Shivaani Kummar
    Department of Medicine and Pharmacology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 10:85-96. 2011
    ..Treatment with PHY906 did not alter the pharmacokinetics of 5-FU, irinotecan, or the irinotecan metabolite SN-38...
  15. pmc Role of cysteine amino acid residues on the RNA binding activity of human thymidylate synthase
    Xiukun Lin
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Healthcare System, New Haven, CT 06520, USA
    Nucleic Acids Res 31:4882-7. 2003
    ..Taken together, these findings identify Cys-180 as a critical residue for the in vitro and in vivo translational regulatory effects of human TS...
  16. ncbi request reprint Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds
    John C Schmitz
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VACT Cancer Center IIID, VACT Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
    Cancer Res 64:1431-5. 2004
    ..These studies suggest that TS-targeted siRNAs are effective inhibitors of TS expression and may have therapeutic potential by themselves or as chemosensitizers in combination with TS inhibitor compounds...
  17. ncbi request reprint An update on treatment advances for the first-line therapy of metastatic colorectal cancer
    James J Lee
    Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
    Cancer J 13:276-81. 2007
    ....
  18. pmc Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity
    Shao Yu Wu
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Nucleic Acids Res 41:4650-9. 2013
    ..The strategy of designing siRNA molecules that incorporate cytotoxic nucleosides represents a potentially novel drug development approach for the treatment of cancer and other human diseases...
  19. pmc Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique
    Wei Zhang
    Department of Pharmacology, Section of Medical Oncology, Yale School of Medicine, New Haven, CT 06520, USA
    Biochem Pharmacol 82:411-7. 2011
    ..This LC/MS/MS assay is simple, fast, and sensitive, and it represents a significant advance over previously published methodologies...
  20. ncbi request reprint Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 5:S60-1. 2005
  21. pmc Identification of critical amino acid residues on human dihydrofolate reductase protein that mediate RNA recognition
    Ningwen Tai
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Healthcare System, New Haven, CT 06520, USA
    Nucleic Acids Res 30:4481-8. 2002
    ....
  22. ncbi request reprint Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells
    Abby L Mulkeen
    Department of Surgery, Yale Cancer Center, New Haven, Conn, USA
    Arch Surg 141:367-74; discussion 374. 2006
    ..We hypothesize that VEGF inhibition will result in decreased cellular proliferation...
  23. doi request reprint Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes
    M Wasif Saif
    Developmental Therapeutics Program, Yale Cancer Center, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Natl Cancer Inst 101:1543-52. 2009
    ..We review the data on pharmacokinetically guided dose adjustment of 5-FU and discuss the potential of this approach to advance therapeutic outcomes...
  24. ncbi request reprint Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies
    Muhammad Wasif Saif
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
    Oncology (Williston Park) 20:11-9. 2006
    ..In this article we review various treatment options, including cytotoxic and targeted agents, currently available for patients with mCRC...
  25. ncbi request reprint Lessons learned from the Saltz and Mayo Clinic regimens
    Edward Chu
    Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
    Clin Colorectal Cancer 2:13. 2002
  26. ncbi request reprint Thymidylate synthase as a translational regulator of cellular gene expression
    Jun Liu
    Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, USA
    Biochim Biophys Acta 1587:174-82. 2002
    ..Finally, the ability of TS to function as a translational regulator may have important consequences with regard to the development of cellular resistance to various anticancer drugs...
  27. doi request reprint Biology of colorectal cancer
    Muhammad Wasif Saif
    From the Section of Medical Oncology and Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
    Cancer J 16:196-201. 2010
    ..These targeted therapies can then be used alone or in combination with standard cytotoxic chemotherapy regimens...
  28. ncbi request reprint Can metastatic colorectal cancer be cured?
    David L Bartlett
    Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15232, USA
    Oncology (Williston Park) 26:266-75. 2012
    ..This article reviews the main issues that must be considered from the surgical oncology and medical oncology perspectives, respectively...
  29. ncbi request reprint New developments at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    Edward Chu
    Chief, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT
    Clin Colorectal Cancer 4:358. 2005
  30. pmc Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)
    Wei Zhang
    Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    J Chromatogr A 1217:5785-93. 2010
    ..These findings demonstrated that LC/MS/MS was and effective and reliable method for studying the parent chemicals of the Chinese herbal medicine PHY906 and their metabolites in a patient with metastatic colorectal cancer...
  31. ncbi request reprint A novel methionine-based signaling mechanism regulating the expression of thymidylate synthase
    Edward Chu
    Department of Medicine, Yale Cancer Center, Yale School of Medicine, West Haven, Connecticut, USA
    Cancer Biol Ther 2:370-1. 2003
  32. doi request reprint A history of cancer chemotherapy
    Vincent T DeVita
    Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Res 68:8643-53. 2008
    ..Today, chemotherapy has changed as important molecular abnormalities are being used to screen for potential new drugs as well as for targeted treatments...
  33. ncbi request reprint A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer
    John Murren
    Yale New Haven Cancer Center, New Haven, CT, USA
    Invest New Drugs 23:123-35. 2005
    ..A phase I trial was initiated to determine the toxicities, maximum tolerated dose, and pharmacokinetics of VNP40101M by short IV infusion...
  34. pmc Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers
    Hussein Tawbi
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27E, 5117 Centre Avenue, Pittsburgh, PA, 15213 1863, USA
    Cancer Chemother Pharmacol 73:207-11. 2014
    ..We aimed to evaluate whether use of calcium carbonate has a significant effect on imatinib pharmacokinetics...
  35. pmc Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors
    John C Schmitz
    VACT Healthcare System, VACT Cancer Center, West Haven, CT, USA
    Silence 2:1. 2011
    ..abstract:..
  36. doi request reprint Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era
    Roland El-Ghazal
    Hospital of St Raphael, New Haven, CT, USA
    Clin Colorectal Cancer 10:142-5. 2011
    ..This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management...
  37. ncbi request reprint The role of a drug holiday: revisited
    Edward Chu
    Clin Colorectal Cancer 6:554-5. 2007
  38. ncbi request reprint Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002
    Kavita Maung
    Clin Colorectal Cancer 2:140-5. 2002
  39. ncbi request reprint The role of a drug holiday: even patients with cancer need a vacation
    Edward Chu
    Clin Colorectal Cancer 6:182. 2006
  40. ncbi request reprint Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers
    Everett E Vokes
    The University of Chicago Medical Center and Cancer Center Chicago, Illinois, USA
    Oncology (Williston Park) 20:15-25. 2006
    ..Ongoing trials continue to investigate both the monoclonal antibodies and TKIs in various treatment settings...
  41. ncbi request reprint Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-Fluorouracil toxicity
    Edward Chu
    Clin Colorectal Cancer 4:150. 2004
  42. ncbi request reprint Adjuvant therapy: new treatment options
    Edward Chu
    Clin Colorectal Cancer 4:219-20. 2004
  43. ncbi request reprint Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer
    Edward Chu
    Clin Colorectal Cancer 4:16. 2004
  44. ncbi request reprint Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer
    Edward Chu
    Clin Colorectal Cancer 3:205. 2004
  45. ncbi request reprint The role of thymidylate synthase as a molecular biomarker
    Antontello DiPaolo
    Clin Cancer Res 10:411-2. 2004
  46. ncbi request reprint Validation of the role of angiogenesis as a chemotherapeutic target
    Edward Chu
    Clin Colorectal Cancer 3:74-5. 2003
  47. ncbi request reprint The role of stool DNA analysis in the early detection and screening of colorectal cancer
    Edward Chu
    Clin Colorectal Cancer 3:9. 2003
  48. ncbi request reprint Colorectal cancer awareness month
    Edward Chu
    Clin Colorectal Cancer 5:389. 2006
  49. ncbi request reprint Clinical colorectal cancer: the epidermal growth factor receptor signaling pathway as a chemotherapeutic target
    Edward Chu
    Clin Colorectal Cancer 2:202-3. 2003
  50. ncbi request reprint Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability
    Lori Johnson
    Clin Colorectal Cancer 2:146-8. 2002
  51. ncbi request reprint Oxaliplatin: a welcome addition to our therapeutic armamentarium
    Edward Chu
    Clin Colorectal Cancer 2:72. 2002
  52. ncbi request reprint Colorectal cancer: targeting metastasis and angiogenesis
    Edward Chu
    Clin Colorectal Cancer 1:200. 2002
  53. ncbi request reprint Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008
    Tara Beers Gibson
    Clin Colorectal Cancer 7:233-9. 2008
  54. ncbi request reprint The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer
    Edward Chu
    Clin Colorectal Cancer 4:292. 2005
  55. ncbi request reprint Sequence analysis and functional study of thymidylate synthase from zebrafish, Danio rerio
    Changqing Du
    Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China
    J Biochem 139:913-20. 2006
    ..1-CMV/TS, was constructed which targeted the protein-coding region of zebrafish TS mRNA. Significant change in the development of tail and epiboly was found in zebrafish embryos microinjected pSilencer4.1-CMV/TS siRNA expression vector...
  56. ncbi request reprint Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer
    Edward Chu
    Clin Colorectal Cancer 6:13. 2006
  57. ncbi request reprint The potential role of gene profiling in the management of early-stage colon cancer
    Edward Chu
    Clin Colorectal Cancer 6:99. 2006
  58. ncbi request reprint 2006 - the year in review
    Edward Chu
    Clin Colorectal Cancer 6:256-7. 2006
  59. ncbi request reprint Targeted therapy
    Edward Chu
    Clin Colorectal Cancer 6:336. 2007
  60. ncbi request reprint Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapy
    Edward Chu
    Clin Colorectal Cancer 5:80-1. 2005
  61. ncbi request reprint Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells
    Jingfang Ju
    Cancer Genomics Laboratory, Mitchell Cancer Institute USA, Mobile, Alabama 36688, USA
    Clin Cancer Res 13:4245-51. 2007
    ..The purpose of the study is to investigate the regulation of p53 expression in response to 5-fluorouracil (5-FU) in human colon cancer cells...
  62. ncbi request reprint Clinical colorectal cancer: new advances in screening
    Edward Chu
    Clin Colorectal Cancer 5:312. 2006
  63. ncbi request reprint The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer
    Erin Grothey
    Clin Colorectal Cancer 6:621-4. 2007
  64. ncbi request reprint Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity
    Sae Hee Ko
    Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:289-97. 2006
    ..The aim of this study was to determine whether hyperthermia could further augment the efficacy of temozolomide, an alkylating agent, against melanoma and improve its therapeutic index in a rat model of isolated limb infusion...
  65. ncbi request reprint Lessons learned from Mother Nature
    Edward Chu
    Clin Colorectal Cancer 5:232. 2005
  66. ncbi request reprint Making sense out of antisense thymidylate synthase
    Edward Chu
    Clin Colorectal Cancer 5:12. 2005
  67. doi request reprint Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer
    Edward Chu
    J Clin Oncol 26:2224-6; author reply 2228. 2008
  68. doi request reprint Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression
    Edward Chu
    Clin Colorectal Cancer 7:162. 2008
  69. doi request reprint Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study
    Edward Chu
    Clin Colorectal Cancer 7:226. 2008

Research Grants16

  1. Molecular Regulation of Translational Regulation
    Edward Chu; Fiscal Year: 2007
    ..In this aim, we propose to identify the cellular mRNAs in addition to DHFR mRNA whose expression and/or function may be under the control of human DHFR protein. ..
  2. MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION
    Edward Chu; Fiscal Year: 2005
    ..Moreover, these molecular-based studies may provide the rational basis for the development of novel therapeutic strategies for human cancer. ..
  3. MOLECULAR BASIS FOR TRANSLATIONAL REGULATION
    Edward Chu; Fiscal Year: 2003
    ..As part of this aim, we plan to identify the domain or domains on the DHFR protein as well as the critical amino acid contact points that mediate the process of RNA binding. ..
  4. MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION
    Edward Chu; Fiscal Year: 1999
    ..Specifically, the applicant plans to identify the domain or domains on the TS protein as well as the critical amino acid contact points that mediate the process of RNA binding. ..